Answers are grounded in this paper and cite their sources.
Demonstrates enhanced tumor control in mice using mRNA vaccines with 4-1BB costimulation, suggesting a new therapy method.
Introduction Although mRNA—lipid nanoparticle (mRNA-LNP) vaccines are being explored as cancer immunotherapies, their clinical application is constrained by the need for personalized identification of tumor neoantigens and time-consuming vaccine design. Here, we investigated whether an off-the-shelf, antigen-mismatched mRNA-LNP vaccine could elicit bystander anti-tumoral effects without the need to express any tumor antigen. Methods C57BL/6 mice were challenged subcutaneously with 1x10^6 B16 melanoma cells, and five days later, they were immunized intratumorally with an mRNA-LNP encoding an irrelevant antigen, ovalbumin (mRNA-OVA), either alone or in combination with a tolerable dose of 4-1BB agonistic antibodies (50 μg of clone 3H3, administered intraperitoneally). Results Remarkably, mRNA-OVA vaccination alone resulted in robust tumor control despite the absence of any tumor antigen. Notably, mice mounting the strongest OVA-specific CD8 T cell responses exhibited the greatest tumor control, suggesting a role for bystander CD8 T cell activation in potentiating anti-tumoral activity. Importantly, the anti-tumoral efficacy of mRNA-LNP vaccination was further enhanced when combined with a low dose of costimulatory anti-4-1BB antibodies. This costimulatory anti-4-1BB regimen was well tolerated and did not result in elevated liver enzyme levels in mice. Mechanistically, mRNA vaccination induced potent type I interferon (IFN-I) responses, which increased the expression of costimulatory molecules, rendering tumors more responsive to costimulatory triggering. Conclusion Together, these findings demonstrate that mRNA-LNP vaccines promote anti-tumor immunity and can synergize with 4-1BB costimulation to enhance tumor control, providing a mechanistic rationale for combining mRNA vaccines with costimulatory immunotherapies.
No takes yet. Share an insight, caveat, or question.
Dangi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: